Tacrolimus is linked to risks.

The content was based on data from 2 trials (1 conducted in the United States and 1 in Europe) that compared the contraceptive and effectualness of tacrolimus- and cyclosporine-based regimens in bravery operation.


Results of the studies showed that use of tacrolimus and cyclosporine yielded similar life rates at 12 and 18 months, respectively (93.5% for tacrolimus vs 86.1% for cyclosporine at 12 months; 91.7% for tacrolimus vs 89.8% for cyclosporine at 18 months).


Tacrolimus is linked to risks for neurotoxicity, renal social function scathe, illegality, and posttransplant diabetes mellitus. As with most regimens such as this, use of tacrolimus-based immunosuppression is also linked to an increased risk for malignancies, particularly nonmelanoma skin cancers.


The recommended starting oral dose of tacrolimus in mettle surgical procedure recipients is 0.075 mg/kg/day (in divided doses 12 period of time apart), initiated no sooner than 6 period posttransplantation. Dosing should be titrated based on clinical assessments of act and tolerability, and construction therapy with corticosteroids is recommended during early posttransplantation.